Cost-effectiveness of Respiratory Syncytial virus Infection (RSV) Prophylaxis with Palivizumab in Preterm Infants in Colombia

Juan-David Rueda (), Diego Rosselli () and Juan Gabriel Ruiz-Peláez ()

Coyuntura Económica, 2013

Abstract: Introducción: El virus sincitial respiratorio (VSR) afecta a ninos de toda las edades, pero tiene consecuencias más serias en los prematuros. El objetivo de este trabajo es evaluar la costo-efectividad de palivizumab para la profilaxis del VSR en recién nacidos menores de 35 semanas en Colombia.

Keywords: Palivizumab; Virus Sincitial Respiratorio; Recién Nacidos Prematuros; Análisis de Costo-Efectividad; Asma. Keywords: Palivizumab; Respiratory syncytial virus; Preterm infants; Cost-effectiveness analysis; Asthma (search for similar items in EconPapers)
JEL-codes: I12 I13 I18 (search for similar items in EconPapers)
Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/11445/267

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:col:000438:012043

Access Statistics for this article

More articles in Coyuntura Económica from Fedesarrollo Contact information at EDIRC.
Bibliographic data for series maintained by Patricia Monroy ().